Abstract: This disclosure demonstrated that cyanobacteria bioengineered with cyanobacterial lipid-biosynthetic-promoting genes could produce large quantities of SDA, as well as rarely observed ETA. Importantly, the biosynthesized omega-3 fatty acids, such as SDA and ETA, are found conjugated to more bioavailable glycolipids, including MGDG and DGDG. Novel compositions include MGDG, DGDG, SQDG, and PG molecular species that contain the following n-3 PUFAs and n-3 LC-PUFAs at both sn-1 and sn-2 positions: 18:3/18:4, 18:3/20:4, 18:3/20:5, 18:4/18:4, 18:4/20:4, 18:4/20:5. These compositions are not found in nature and result from the engineering of cyanobacteria; and can serve as highly bioavailable, cost-effective anti-inflammatory compounds. These compositions, therefore, have strong anti-inflammatory properties with the likely capacity to block activities of cyclooxygenases, lipoxygenases, and cytochrome P450s that metabolize PUFAs and LC-PUFAs to pro-inflammatory mediators.

Abstract: Provided herein are biomarkers for screening and monitoring of conditions, diseases, and disorders. In particular, provided herein are sPLA2 biomarkers for use in characterizing, prognosing, and treating disorders associated with elevated sPLA2.

Abstract: The present invention relates to recombinant vectors, modified microorganisms, and methods for omega-3 polyunsaturated fatty acid production.

Abstract: The present invention relates to recombinant vectors, modified microorganisms, and methods for omega-3 polyunsaturated fatty acid production.

Abstract: Compositions and methods for identifying and treating patients having altered capacity for LC-PUFA production are disclosed.

Abstract: Compositions and methods for identifying and treating patients having altered capacity for LC-PUFA production are disclosed.

Abstract: The present invention provides methods of identifying a subject as responsive to treatment of an inflammatory disease and/or inflammation with one or more polyunsaturated fatty acids (PUFAs), comprising detecting, in a nucleic acid sample of a subject having an inflammatory disease and/or inflammation, the presence of a C allele at single nucleotide polymorphism (SNP) rs730012 in the leukotriene C4 synthase gene, wherein the presence of said C allele at rs730012 in said nucleic acid sample from the subject indicates that the subject is responsive to treatment of said inflammatory disease and/or inflammation with one or more PUFAs.

Abstract: Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of ?5 desaturase, and optionally stearidonic acid or ?-3 arachidonic acid. Preferred formulations may be in the form of a good tasting,.preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.

Abstract: The present invention provides methods of treating an inflammatory disorder, or a disorder having an inflammatory component, in a mammalian subject in need of such treatment by administering to said subject an effective amount of a composition in unit dosage form for delivery of a daily dose of said composition, said composition consisting essentially of: (i) an effective amount of ?-linolenic acid (GLA) for increasing dihomogammalinolenic acid (DGLA) levels in the inflammatory cells of said mammalian subject, thereby inhibiting the metabolism of arachidonic acid; (ii) an effective amount of a ?5 desaturase inhibitor for inhibiting accumulation of arachidonic acid in the serum of said mammalian subject; and, optionally, (iii) an effective amount of a competitive inhibitor of arachidonic acid metabolism. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder.

Abstract: The present invention provides methods of identifying a subject having an increased or decreased ability to convert medium chain-polyunsaturated fatty acids (MC-PUFAs) to long chain polyunsaturated fatty acids (LC-PUFAs), comprising: (a) correlating the presence of one or more than one genetic marker in chromosome 11ql2-13, between build 37.1 position 61548559 and build 37.1 position 61560261, with an increased ability to convert MC-PUFAs to LC-PUFAs; and b) detecting the one or more than one genetic marker of step (a) in the subject, thereby identifying the subject as having an increased ability to convert MC-PUFAs to LC-PUFAs. Also provided are methods of correlating one or more genetic markers with an ability to convert MC-PUFAs to LC-PUFAs.

Abstract: Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of ?5 desaturase, and optionally stearidonic acid or ?-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.

Abstract: Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of &Dgr;5 desaturase, and optionally stearidonic acid or &ohgr;-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.

Abstract: The present invention is directed towards the control of inflammation. More specifically there are provided herein dietary fatty acid regimens that may be used to inhibit the increase of serum arachidonic acid when GLA is provided as a dietary supplement.

Abstract: This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

Abstract: This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier.This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).